Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2006

01-02-2006 | Clinical trial

Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer

Authors: Anne Fleissig, Lesley J. Fallowfield, Carolyn I. Langridge, Leigh Johnson, Robert G. Newcombe, J. Michael Dixon, Mark Kissin, Robert E. Mansel

Published in: Breast Cancer Research and Treatment | Issue 3/2006

Login to get access
Metadata
Title
Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer
Authors
Anne Fleissig
Lesley J. Fallowfield
Carolyn I. Langridge
Leigh Johnson
Robert G. Newcombe
J. Michael Dixon
Mark Kissin
Robert E. Mansel
Publication date
01-02-2006
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9025-7

Other articles of this Issue 3/2006

Breast Cancer Research and Treatment 3/2006 Go to the issue

OriginalPaper

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer

Clinical Trails

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance

Preclinical study

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling

Review

EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization

Epidemiology

Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium

Review

Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits